In patients with moderate to advanced stage CKD, normophosphatemia is maintained by the action of FGF23 and PTH to augment phosphaturia, but the progression of CKD together with decreased expression of renal Klotho leads to a reduction in the ability of the kidney to excrete urinary phosphate, leading to the development of overt hyperphosphatemia. The gene discussed is PTH; the disease is chronic kidney disease.